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Scan this QR code Background • Key concepts in chronic obstructive pulmonary disease (COPD) which have a significant impact on patient's health-related quality of life (HRQoL) are dyspnea, chest tightness, wheeze, cough, sputum production, and exacerbations. 1, 2 • Important areas within physical functioning such as activities of daily living, sleep, and fatigue are affected. 3, 4 Emotional wellbeing, and work productivity are also impacted. 2, 5 • Despite the severity of this condition, adherence to treatment is generally low. 6 • Patient-reported outcomes (PROs) are essential in COPD to evaluate overall HRQoL, symptoms, impact on activities of daily living, and treatment response. Also, patient-reported outcome measures (PROMs) have been used for the detection, quantification, and evaluation of COPD exacerbations. 7, 8 • Regulatory authorities such as the U.S. Food and Drug Administration (FDA), and the European Medicines Agency (EMA), share the view that patients' perspective is important during the development and approval process of new drugs. 9 • PROs are widely used as effectiveness endpoints in COPD clinical studies. Traditionally, both generic (e.g., the 36-Item Short Form Health Survey [SF-36]) and disease-specific PROMs (e.g., the St. George's Respiratory Questionnaire [SGRQ]) have been used. 7
Objective
• To provide an overview of PRO endpoints in completed randomized controlled trials (RCTs) of commonly used and approved COPD drug therapies.
Methods
• A cross-sectional, descriptive review of completed clinical trials posted on the "ClinicalTrials.gov" database as of October 2017 was conducted.
• RCTs assessing commonly used and approved COPD therapies were included. These were indacaterol, roflumilast, aclidinium, umeclidinium, fluticasone, glycopyrronium, olodaterol, tiotropium, vilanterol, salmeterol, formoterol, budesonide, and beclomethasone, either as monotherapy or as their combinations.
• The search was restricted to completed phase III and IV trials only. Articles published in English were retrieved. There was no restriction on the time-frame of the search. Also, there were no limitations on age group or gender of COPD patients included in the trials.
• Terminated, recruiting, or withdrawn trials were excluded, as well as studies not having any PRO endpoint. • The main outcomes included data and description related to disease-specific PRO (primary, secondary, exploratory, and non-specified) endpoints used across the studies.
• Both validated and unvalidated PROMs were included in the analyses. No generic and health utility measures were included in this overview.
• A conceptual framework was developed based on literature available on HRQoL in COPD and guidelines such as Global Initiative for Chronic Obstructive Lung Disease [GOLD] 2018 1 and ATS/ERS guidelines 2 (see Figure 1 ). The conceptual framework served as the basis to inform on key impacted domains.
Results
• Figure 1 provides an overview of impacted COPD domains, along with etiology and contributing factors. Symptoms affect HRQoL leading to impacted physical functioning, psychosocial, and economic areas. Treatment impact as an important aspect of HRQoL was included in this framework.
Figure 1: Overview of the impact of COPD symptoms on HRQoL

Contributing factors
Poor This conceptual framework is based on the GOLD guidelines (2018), ATS/ERS guidelines, and literature on the impact of COPD on HRQoL. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] • A total of 88 clinical trials were included and the results presented are mutually inclusive. Symptom-based and HRQoL measures were frequently included to assess health status of COPD patients during the course of treatment.
• Both validated and unvalidated PROMs were used to capture symptoms, while only validated instruments were used to capture HRQoL in the trials (see Table 1 ).
• To capture HRQoL, studies widely used SGRQ (n=65). Three studies used SGRQ as the primary endpoint while, all remaining used it as secondary, exploratory, or other pre-specified endpoints.
• Besides the symptom-specific PROMs, symptoms were captured by clinical endpoints (not reported in this overview), interviewer/clinician based endpoints (BDI/TDI), or unvalidated instruments to assess the severity and frequency of symptoms, frequently using an e-diary. • Table 2 summarizes the domain-level analyses of PROMs in the included trials. Each PROM was analysed for its respective domain. Domains included were symptom and its impact, sleep, energy, activities of daily living, psychosocial, treatment impact, work, and others.
• Amongst symptoms, dyspnea and its impact are the most elaborately reported domains (see Table 2 ), when all the instruments were compared.
• Amongst HRQoL, domains such as sleep, fatigue, daily activities, and emotional concerns are covered in the PROMs. These domains are not scored separately, but a total score is calculated in most of the instances.
• Despite availability of PROMs covering affected areas including sleep, fatigue, anxiety and depression, treatment burden, activities of daily living etc., a gap exists owing to their lack of use.
• Total scores of commonly used COPD PROMs cannot capture improvements/deteriorations in such impacted domains effectively. 
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Overall health is included in SGRQ-C, but not in the total score $ Precipitation/increase in symptoms due to environmental exposure # E-RS:COPD (11 item) is a subscale of EXACT-PRO focusing on respiratory symptoms. Hence, it is not presented separately in Table 2 CRQ-SAS is an HRQoL instrument. However, in clinical trials, only dyspnea domain (CRQ-SAS dyspnea score) was used; hence, classified under symptom † EMSCI/NiSCI items are included based on the available literature, as these instruments were not available in public domain at the time of execution of study Unvalidated instruments are not included in Table 2 Conclusion • Overall, HRQoL was covered by disease-specific PROMs (mainly by SGRQ) and symptoms by variety of endpoints in the analysed COPD clinical trials. However, from a patient's perspective, a uniform approach for assessment of symptoms (and their impact) is lacking.
•
Inclusion of measures covering additional impacted domains like sleep, fatigue, and activities of daily living should be considered when designing a clinical trial.
Careful planning for inclusion of PROs based on the aim of a study, capturing all impacted disease-related areas (as observed in the conceptual framework), without increasing administrative burden to patients may contribute towards a comprehensive patient-centered assessment.
